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Summary
We have recently identified glucose-regulated protein-78 (GRP78) as a relevant molecular target expressed in metastatic
tumors by fingerprinting the circulating repertoire of antibodies from cancer patients. Here we design and evaluate a
ligand-receptor system based on the tumor cell membrane expression of GRP78. We show that GRP78 binding peptide
motifs target tumor cells specifically in vivo and in human cancer specimens ex vivo. Moreover, synthetic chimeric peptides
composed of GRP78 binding motifs fused to a programmed cell death-inducing sequence can suppress tumor growth in
xenograft and isogenic mouse models of prostate and breast cancer. Together, these preclinical data validate GRP78 on
the tumor cell surface as a functional molecular target that may prove useful for translation into clinical applications.
Introduction teractions in solid phase, cell lines, xenograft and isogenic tumor
models in mice, and human cancer specimens.
Here we introduce two ligand peptides that can specificallyThe membrane compartment of cells in tumors contains many
receptors that are required for their survival. In particular, mem- (1) bind to GRP78 in a cell-free system, (2) target cell surfaces
in vitro, (3) home in vivo to tumors in mouse models of breastbers of the unfolded protein response (Kaufman, 1999; Lee,
2001; Reddy et al., 2003), such as the glucose-regulated protein and prostate cancer, (4) suppress tumor growth when synthe-
sized as a fusion chimeric peptide with a proapoptotic se-and the heat shock protein families, are candidate targets on
the tumors; the presence and functionality of this subset of quence, and finally (5) bind to patient-derived cancer samples.
Together, these data indicate that GRP78 is a functional molecu-chaperone proteins in signal transduction, drug resistance, apo-
ptosis, and immunomodulation has recently begun to be recog- lar target on tumor cell surfaces in vivo. This ligand-receptor
system may yield targeted therapy applications and should benized (Beere et al., 2000; Lee, 2001; Kamal et al., 2003; Mintz
et al., 2003; Neckers and Lee, 2003; Nicchitta, 2003; Ravagnan considered for validation against primary and metastatic tu-
mors.et al., 2001; Reddy et al., 2003; Shin et al., 2003).
By screening combinatorial peptide libraries, we identified
one such glucose-regulated protein family member, glucose- Results
regulated protein-78 kDa (GRP78), as a tumor antigen through
epitope mapping of the humoral immune response from cancer Choice of GRP78 binding peptides and initial
evaluation of targeting vectorspatients (Mintz et al., 2003). Because GRP78 confers a protec-
tive cellular response against stress conditions present in solid To design the targeting vectors that were used here, we evalu-
ated a panel of four predicted GRP78 binding motifs (Blond-tumors (Jamora et al., 1996; Koong et al., 1994; Li et al., 1992;
Miyake et al., 2000; Reddy et al., 2003; Sugawara et al., 1993), Elguindi et al., 1993) in phage binding assays. Among the con-
sensus peptide motifs tested in our phage-targeting system,we hypothesized that GRP78 expressed on the cell surface of
cancer cells (Mintz et al., 2003; Shin et al., 2003) could serve the ligand peptides WIFPWIQL and WDLAWMFRLPVG showed
the best targeting activity and specificity to GRP78, relativeas a functional receptor in vivo. In order to evaluate whether
GRP78 ligands would allow targeting of solid tumors, we de- to control proteins (Supplemental Figure S1 at http://www.
cancercell.org/cgi/content/full/6/3/275/DC1). Given the bindingvised experiments to assess GRP78-based protein-protein in-
S I G N I F I C A N C E
Several lines of evidence indicate that glucose-regulated stress response proteins can (1) serve as functional chaperones on the
tumor cell surface, (2) confer tumor selectivity on specific inhibitors, and (3) regulate multiple signaling pathways related to apoptosis,
immune function, and drug resistance. Thus, we sought to evaluate whether glucose-regulated proteins would be suitable receptors
for systemic targeting of tumors. Our results illustrate the ability of one such glucose-regulated protein, GRP78, to function as a
membrane-associated molecular chaperone that enables tumor targeting. Given the promising therapeutic data in experimental
models and the presence of the receptor in patient-derived samples, this system should be considered for targeted drug development.
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Figure 1. Filamentous phage clones displaying
WIFPWIQL and WDLAWMFRLPVG peptides bind
specifically to GRP78
GRP78, HSP70, HSP90, or BSA was coated on mi-
crotiter wells at 10 g/ml and incubated with
either WIFPWIQL-phage (A) or WDLAWMFRLPVG-
phage (B). An insertless phage (fd-tet) served as
the negative control. Phage input was 109 TU per
well. Results are expressed as mean  standard
error of the mean (SEM) of triplicate wells. Binding
inhibition of WIFPWIQL-phage (C) and WDLAW
MFRLPVG-phage (D) to immobilized GRP78 was
obtained by the addition of the corresponding
synthetic peptides. Microtiter wells were coated
with GRP78 at 10 g/ml, and phage clones were
incubated with increasing concentrations of syn-
thetic cognate or control peptides. Experiments
were performed three times with similar results.
*Student’s t test, p  0.01.
properties of these peptides, we decided to use fUSE5-derived ure 2, left panels), recombinant GRP78 in solution (Figure 2,
phage vector constructs displaying the GRP78 binding motifs middle panels), or the corresponding synthetic peptides (Figure
WIFPWIQL and WDLAWMFRLPVG as fusion peptides to the 2, right panels) inhibited binding. Control isotypic antibodies,
minor coat protein pIII (Smith and Scott, 1993) for further experi- unrelated control proteins, and peptides did not affect binding
ments. of the GRP78 binding phage. These results indicate that GRP78
binding peptides can specifically target cell surfaces.
Cell-free binding of ligand peptides to immobilized
GRP78 is specific
GRP78 binding peptides undergo cell internalizationWe evaluated binding of WIFPWIQL-phage (Figure 1A) and of
Next, we evaluated whether GRP78 would mediate internaliza-WDLAWMFRLPVG-phage (Figure 1B) to recombinant GRP78
tion of a ligand into cells. We used the DU145 line as representa-in microtiter wells. Both WIFPWIQL-phage and WDLAWMF
RLPVG-phage bound significantly more to GRP78 in vitro than
to control proteins, including heat shock protein 70 (HSP70),
heat shock protein 90 (HSP90), and bovine serum albumin
(BSA). Moreover, WIFPWIQL-phage (870-fold; Student’s t test,
p 0.001) and WDLAWMFRLPVG-phage (260-fold; Student’s t
test, p 0.001) bound significantly more to immobilized GRP78
in vitro than did a negative control phage displaying no insert (fd-
tet). We observed a dose-dependent inhibition of WIFPWIQL-
phage (Figure 1C) and WDLAWMFRLPVG-phage (Figure 1D)
binding to GRP78 by the corresponding synthetic peptides;
control peptides with unrelated sequences had no detectable
effect. Together, these data show that ligand peptides displayed
in a filamentous phage specifically bind to immobilized GRP78.
GRP78 binding peptides target cell surfaces in vitro
Having determined the specificity of GRP78 binding peptides to
the immobilized protein in a cell-free system, we next evaluated
binding to human DU145 prostate cancer cells (Figure 2). Bind-
ing of filamentous phage clones displaying WIFPWIQL (Figure
2A) and WDLAWMFRLPVG (Figure 2B) to intact tumor cells was
performed by using an aqueous-organic phase separation assay Figure 2. GRP78-targeted phage binding to tumor cells is specific
(Giordano et al., 2001). Each of the GRP78 binding phage clones The BRASIL method (Giordano et al., 2001) was applied to test the binding
or insertless negative control phage was incubated with DU145 of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or control insertless phage
to the human prostate cancer-derived DU145 cells. Transducing unit countscells. Binding to DU145 cells was at least 30-fold higher (Stu-
of the GRP78 binding clones without inhibition was set to 100% in each case.dent’s t test, p  0.001) with WIFPWIQL-phage or WDLAW
Results are expressed as mean  SEM of triplicates. Binding inhibition ofMFRLPVG-phage compared to fd-tet phage. The GRP78-medi-
both WIFPWIQL-phage (A) and WDLAWMFRLPVG-phage (B) was evaluated
ated interaction of either WIFPWIQL-phage (Figure 2A) or by the addition of a polyclonal anti-GRP78 or an unrelated control antibody
WDLAWMFRLPVG-phage (Figure 2B) to DU145 cell surfaces (left panels), recombinant GRP78 (middle panels), and soluble synthetic
peptides (right panels).was specific given that an anti-GRP78 polyclonal antibody (Fig-
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tive human prostate cancer-derived cells expressing GRP78 on
the cell surface (Mintz et al., 2003) and GRP78 binding phage
as targeted ligands. Each phage clone or control phage was
incubated with cells for 4 hr at 37C. Cells were washed to
remove noninternalized phage, permeabilized, and stained with
an anti-bacteriophage antibody. A Cy3-conjugated secondary
antibody was used to detect the presence and localization of
phage particles. GRP78-targeted phage internalization was tem-
perature dependent and time dependent, being detectable at
8 hr and peaking at 24 hr (data not shown). Both WIFPWIQL-
phage and WDLAWMFRLPVG-phage were internalized into
DU145 cells; only background fluorescence was observed when
nonpermeabilized cells or nontargeted control phage (Figure
3A) were used as negative controls. These results indicate that
the binding peptides WIFPWIQL and WDLAWMFRLPVG can
mediate the internalization of GRP78-targeted phage into cells.
Moreover, in order to show that the internalization of GRP78
binding ligands can also occur outside of the context of targeted
phage constructs, we have also evaluated cell killing in vitro by
the synthetic GRP78 binding peptide WDLAWMFRLPVG fused
to the programmed cell death-inducing domain D(KLAKLAK)2,
an amphipatic  helix-forming antimicrobial peptide (Javadpour
et al., 1996) that preferentially disrupts eukaryotic mitochondrial
membranes upon receptor-mediated internalization (Arap et al.,
2002b; Ellerby et al., 1999; Kolonin et al., 2004; Zurita et al.,
2004). Increasing concentrations of either WDLAWMFRLPVG-
GG-D(KLAKLAK)2 or negative control peptides [an equimolar
admixture of WDLAWMFRLPVG plus D(KLAKLAK)2] were incu-
bated with DU145 cells at 37C, and viability was assessed over
time. To gain insight into the mechanism of peptide internaliza-
tion, we also determined whether endocytosis and GRP78 recy-
cling could be affected by ATPase inhibitors (Schmid and Carter,
Figure 3. GRP78-targeted peptides can mediate ligand-receptor cell inter-1990). Treatment of cells resulted in a dose-dependent decrease
nalizationof cell viability with WDLAWMFRLPVG-GG-D(KLAKLAK)2 relative
WIFPWIQL-phage, WDLAWMFRLPVG-phage, or control insertless phageto controls, and the apoptosis is inhibited by sodium azide
were incubated with human prostate cancer-derived DU145 cells for 4 hr(Figure 3B). Taken together, these data suggest that cell internal-
at 37C to allow phage internalization. Internalized phage clones were
ization of GRP78 binding ligands is likely mediated by an active detected with an anti-phage antibody after cell permeabilization (see the
GRP78-dependent mechanism. Experimental Procedures).
A: WIFPWIQL-phage and WDLAWMFRLPVG-phage were internalized into
DU145 cells relative to cells incubated with an insertless control phage; cellsGRP78 binding phage home to tumors upon systemic
incubated with no phage are also shown to assess staining background.administration
B: DU145 cells were incubated with increasing concentrations (up to 20
To determine the ability of GRP78 binding phage clones to M) of the GRP78-targeted proapoptotic peptide WDLAWMFRLPVG-GG-
home to tumors in vivo, we administered WIFPWIQL-phage, D(KLAKLAK)2 or negative control peptides [an equimolar mixture of WDL
AWMFRLPVG plus D(KLAKLAK)2] in the presence or absence of 20 mM sodiumWDLAWMFRLPVG-phage, or control insertless phage intrave-
azide. As described in the Experimental Procedures, viability determinednously to nude mice bearing DU145-derived human prostate
by optical absorbance using a cell proliferation detection reagent withoutcancer xenografts (Figure 4). After 24 hr, the mice were sacri-
any peptide treatment was set to 100%.
ficed, and the tumors and several control organs were collected
and analyzed for phage staining. We observed strong tumor
staining for each GRP78 binding phage clone, while only back-
ground staining was detected in control organs; moreover, neg-
cell death-inducing domain (Arap et al., 2002b; Ellerby et al.,
ative control phage was not detected in tumors or several control
1999; Kolonin et al., 2004; Zurita et al., 2004) would have antitu-organs (Figure 4). It is of note that, as part of the reticulo-
mor effects in vivo. We used nude mice bearing DU145-derivedendothelial system, hepatic and splenic tissues clear circulating
human prostate cancer xenografts (Figures 5A and 5B) or immu-particles (such as phage) nonspecifically and independently of
nocompetent Balb/c mice bearing EF43-fgf4-derived isogenicthe peptides displayed. These data show that human prostate
tumors (Figures 5C and 5D). Mice received weekly doses ofcancer-derived tumor xenografts growing in nude mice can be
targeted peptides or controls. Posttreatment mean tumor vol-targeted by GRP78 binding phage in vivo.
umes in the groups treated with the targeted GRP78 binding
chimeric peptides WIFPWIQL-GG-D(KLAKLAK)2 (Figures 5A andGRP78-targeted proapoptotic synthetic peptides
5C) or WDLAWMFRLPVG-GG-D(KLAKLAK)2 (Figures 5B and 5D)suppress tumor growth
were significantly lower (Student’s t test, p  0.002 in eachWe next sought to establish whether synthetic chimeras com-
posed of the GRP78 binding peptides fused to the programmed case) relative to controls treated with vehicle alone. The sup-
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Figure 4. Immunohistochemical staining of GRP78-targeted phage after systemic administration into human prostate cancer xenograft-bearing mice
Insertless phage fd-tet (negative control), RGD-4C phage (positive control), or phage displaying the GRP78 binding peptides WIFPWIQL and WDLAWMFRLPVG
were intravenously administered into mice bearing DU145-derived prostate carcinoma xenografts. Phage clones were allowed to circulate for 24 hr,
and tissues were recovered and stained as described in the Experimental Procedures. A strong phage staining was observed with WIFPWIQL-phage or
WDLAWMFRLPVG-phage in tumor xenografts. Little or no staining was observed either with fd-tet phage or with GRP78 binding phage clones in control
organs. Scale bar, 100 m.
pression of tumor growth was slightly less efficient in mice studied regardless of whether or not they were tumor cells
(Supplemental Figure S2 at http://www.cancercell.org/cgi/con-bearing EF43-fgf4 tumors, likely reflecting the aggressiveness
of the model. Tumors in mice treated by equimolar mixtures of tent/full/6/3/275/DC1). These contrasting results indicate that
GRP78-mediated cell death in vitro (Supplemental Figure S2)either WIFPWIQL plus D(KLAKLAK)2 or WDLAWMFRLPVG plus
D(KLAKLAK)2 behaved similarly to those tumors in mice that does not recapitulate the selective induction of tumor cell apo-
ptosis in vivo (Figure 5); such paradox might be due to thereceived vehicle only, indicating that untargeted D(KLAKLAK)2
with GRP78 binding peptides had no detectable effect on tumor upregulation of stress response proteins (such as GRP78, one
of the hallmarks of the unfolded protein response), which isgrowth.
likely to occur in cells grown in vitro, outside of their optimal
in vivo physiological conditions. In fact, very recently it becameGRP78-mediated cell apoptosis in vitro does not model
clear that GRP78 promoter-driven expression of a reportertherapeutic in vivo targeting
transgene is undetectable in all the major organs evaluated inTo address whether the presence of GRP78 as a target on the
adult mice (such as liver, spleen, kidney, brain, lung, heart, andcell surface is related to the unfolded protein response (Kauf-
pancreas); in contrast, the GRP78 promoter is highly activeman, 1999; Lee, 2001; Reddy et al., 2003) rather than an inherent
in tumors (Dong et al., 2004). Consistently, we have detectedfeature of tumors per se, we examined both malignant and
programmed cell death induction by TUNEL staining in DU145-nonmalignant cells in vitro. First, we performed fluorescence-
derived tumor xenografts but not in control organs, in agreementactivated cell surface (FACS) analysis of a representative panel
with GRP78 promoter studies in tumor-bearing mice (Supple-of human and mouse cell lines, including tumor cells of epithelial
mental Figure S3; Dong et al., 2004).and nonepithelial origin, as well as nonmalignant cells. We de-
tected positive surface staining, indicating broad membrane
expression of GRP78 in all the lines cultured in vitro (data not GRP78 binding phage clones recognize human
prostate cancer samplesshown). Next, to confirm the functional relevance of the surface
expression of GRP78, we have evaluated targeted cell killing in Because we found GRP78 expression to be high in human
prostate cancer (Mintz et al., 2003), we used phage overlayvitro by GRP78 binding peptides chimerized with the D(KLAKLAK)2
proapoptotic motif (Arap et al., 2002b; Ellerby et al., 1999; Ko- assays (Arap et al., 2002a; Zurita et al., 2004) to determine
whether the GRP78-targeting phage would bind to bone marrowlonin et al., 2004; Zurita et al., 2004). Consistently, as cultured
cells grown in vitro appear to express GRP78 at the membrane metastases from patient-derived prostate cancer. To evaluate
whether the GRP78 binding phage could inhibit the anti-GRP78level, we have observed programmed cell death in all cell lines
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Figure 5. Treatment of tumor-bearing mice with GRP78-targeted proapo-
ptotic peptides
We used nude mice bearing DU145-derived human prostate cancer xeno-
grafts (A and B) or Balb/c mice bearing EF43-fgf4 murine breast carcinoma
tumors (C and D). The synthetic GRP78-targeted proapoptotic peptides
Figure 6. Inhibition of anti-GRP78 antibody staining by GRP78 binding phageWIFPWIQL-GG-D(KLAKLAK)2 and WDLAWMFRLPVG-GG-D(KLAKLAK)2 were
Serial tissue sections of bone marrow metastases from human prostate can-used in each tumor model. Individual tumor volumes are represented before
cer were incubated with the WIFPWIQL-phage, WDLAWMFRLPVG-phage,(filled circles) and after (open circles) treatment for the synthetic GRP78-
or negative control phage prior to adding an anti-GRP78 antibody to thetargeted proapoptotic peptides WIFPWIQL-GG-D(KLAKLAK)2 (A and C) and
sections. Strong staining was observed when the anti-GRP78 antibody wasWDLAWMFRLPVG-GG-D(KLAKLAK)2 (B and D). Controls used were vehicle
used with no phage (A), compared to a negative control antibody withalone and equimolar mixtures of unconjugated WIFPWIQL plus D(KLAKLAK)2
the same isotype and concentration (B). Preincubation with WIFPWIQL-for A and C or WDLAWMFRLPVG plus D(KLAKLAK)2 for B and D. In each case,
phage (C) or WDLAWMFRLPVG-phage (D) inhibited the staining by the anti-mean tumor volumes were significantly smaller (Student’s t test, p  0.001)
GRP78 antibody, whereas a negative control phage with no peptide didin mice treated with the GRP78-targeted proapoptotic peptides relative to
not affect the staining of the anti-GRP78 antibody (E). An eosin staining ofvehicle or to the corresponding control peptides.
the tumor is shown in F. Scale bar, 100 m.
antibody staining, WIFPWIQL-phage, WDLAWMFRLPVG-phage,
tochemistry observations. GRP78-targeted phage clones dis-and negative control phage were overlaid on serial human tissue
playing either WIFPWIQL or WDLAWMFRLPVG peptides clearlysections prior to adding the anti-GRP78 antibody or negative
stained prostate cancer tissue, whereas negative control phagecontrol antibody. Consistently, markedly reduced antibody stain-
showed only background staining; GRP78 expression verifieding was observed with each GRP78 binding phage clone but
with an anti-GRP78 antibody served as a positive control (Figurenot with the negative control phage (Figure 6). Moreover, in a
8). Taken together, these results indicate that GRP78-basedreverse experiment, each GRP78 binding phage or negative
ligand-receptor interactions in the context of human prostatecontrol phage was overlaid on serial human tissue sections.
cancer progression are specific.After extensive washing to remove nonspecific binding, samples
were incubated with an anti-bacteriophage antibody. We ob-
Discussionserved a strong staining with the GRP78 binding phage clones
and marked inhibition when an anti-GRP78 antibody was added
Discovery of functional ligand-receptor systems is a critical stepto the slide; in contrast, no inhibition was observed with a control
for the development of targeted therapies. Several lines of evi-antibody (Figure 7).
dence have recently emerged to suggest that stress responseFinally, to evaluate the expression of GRP78 during the
proteins present on the surface of tumor cells may serve asprogression of prostate cancer, we are currently characterizing
molecular targets. First, global profiling of the cell surface pro-the expression of GRP78 in a panel of human prostate cancer
teome of tumor cells has disclosed a relative abundance ofsamples during different tumor stages, including organ-con-
chaperone heat shock and glucose-regulated proteins (Shin etfined, locally advanced, and metastatic disease. Preliminary im-
al., 2003). Second, fingerprinting the repertoire of antibodiesmunohistochemistry analysis suggests that GRP78 can be ex-
derived from cancer patients with phage display random peptidepressed even in early stage prostate cancer, that stage-specific
libraries has identified a conformational mimic motif of one suchupregulation of this target can occur, and that the expression
glucose-regulated protein family member, GRP78, in prostateof GRP78 is strong in metastatic disease (unpublished data).
Overlay assays were again in agreement with such immunohis- cancer. Antibodies against this peptide revealed cell surface
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Figure 7. Inhibition of GRP78 binding phage
staining by anti-GRP78 antibody
Serial tissue sections of bone marrow metastases
from human prostate cancer were incubated
with an anti-GRP78 antibody prior to adding
the WIFPWIQL-phage, WDLAWMFRLPVG-phage,
and negative control phage (fd-tet) to the sec-
tions. Strong staining was observed when the
phage was applied with no antibody (A and D)
or with negative control antibody (B and E). In
contrast, marked reduction in phage staining
was observed with anti-GRP78 antibody (C and
F). Scale bar, 100 m.
expression of GRP78 (Mintz et al., 2003). Third, GRP78 ex- manner, indicating that the interaction between the ligands and
GRP78 is specific. Next, we established that WIFPWIQL-phagepressed on the surface of prostate cancer cells appears to
mediate the signal transduction of 2-macroglobulin (Misra et and WDLAWMFRLPVG-phage clones target GRP78 expressed
on the cell membrane and are likely internalized by an activeal., 2002), a plasma protease inhibitor that binds to prostate-
specific antigen (PSA) as well (Kanoh et al., 2001). Fourth, we receptor-mediated process.
Moreover, to establish whether the GRP78 binding phagehave shown that the humoral response elicited against the
GRP78-mimic motif or against the native GRP78 strongly corre- could home to human prostate cancer xenografts or mouse
breast isogenic tumors in vivo, we administered the phage con-lated with the development of androgen-independent disease
and shorter overall survival in a large population of prostate structs and controls intravenously into tumor-bearing mice. At
24 hr, we observed localization of GRP78 binding phage intocancer patients (Mintz et al., 2003). Fifth, GRP78 is overex-
pressed under conditions often found in tumors (such as isch- the tumors, with barely detectable phage localization to several
control organs. The staining pattern observed in vivo indicatesemia, hypoxia, or glucose deprivation), hence its denomination
as a glucose-regulated stress response protein that plays a that GRP78-mediated targeted phage internalization occurred
in tumor cells. In fact, selective accessibility based on the fenes-central role in the general cellular defense mechanism that is
referred to as the unfolded protein response (Kaufman, 1999; trated and abnormal nature of tumor vasculature might allow
for preferential targeting of tumor cells by GRP78-targeted pro-Lee, 2001; Reddy et al., 2003). Together, these observations
led to efforts to evaluate GRP78 on the tumor cell membrane as apoptotic peptides (Hashizume et al., 2000). We then tested
the therapeutic properties of the GRP78 binding peptides linkeda translational target for therapeutic intervention in the context of
tumors such as metastatic prostate or breast cancers, currently to a proapoptotic motif (Arap et al., 2002b; Ellerby et al., 1999;
Kolonin et al., 2004; Zurita et al., 2004) in vivo. Paradoxically,incurable diseases.
Here, we designed and validated GRP78-based systems for the GRP78-targeted proapoptotic peptides used in this work
seem to promote programmed cell death in vitro in malignant asligand-directed targeting of solid tumors, in particular of prostate
and breast cancer. We generated phage displaying GRP78 bind- well as nonmalignant cells; in contrast, the apoptotic induction
observed in vivo is clearly tumor specific. These data are relevanting peptides by cloning the inserts WIFPWIQL and WDLAWM
FRLPVG into a phage construct and then we studied the proper- because they illustrate that the effects observed are not depen-
dent on the origin of the tumor cells (human versus mouse),ties of these phage clones. First, WIFPWIQL-phage and WDL
AWMFRLPVG-phage bound significantly more to GRP78 than tumor type (prostate cancer versus breast cancer), or immune
status of the host (nude mice versus immunocompetent mice).to related and unrelated control proteins. We also showed that
the synthetic WIFPWIQL and WDLAWMFRLPVG peptides in- Antitumor effects of GRP78-targeted proapoptotic peptides
were equally effective in both models: significant reduction inhibit binding of the corresponding phage in a dose-dependent
Figure 8. GRP78 binding phage overlay of pri-
mary human prostate cancer correlates to
GRP78 expression
Relative to the weak staining observed with a
negative control phage (A), strong staining was
observed with either WDLAWMFRLPVG-phage
(B), WIFPWIQL-phage (C), or anti-GRP78 anti-
body (D), which also served as a positive control
for GRP78 expression.
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tumor volumes when prostate cancer xenografts or murine support to the idea of exploiting the differential humoral immune
response to human cancer (Mintz et al., 2003; Vidal et al., 2004)breast isogenic tumors were treated with the targeted peptides
relative to controls was observed. In agreement with such find- as a promising methodology for identifying targets for therapeu-
tic intervention.ings and the recent GRP78 promoter studies of other investiga-
tors (Dong et al., 2004), we did not detect apoptosis induction
Experimental proceduresin normal tissues upon administration of the GRP78-targeted
proapoptotic peptides. Also, preliminary preclinical studies have
Cell culture and reagents
shown that the maximum tolerated dose (MTD) for these pep- DU145 prostate cancer cells were purchased from the American Type Cul-
tides has not yet been reached (unpublished data), again rein- ture Collection (ATCC; Manassas, VA), and tissue culture was performed
forcing the notion that GRP78 is selectively targeted in our tumor as described (Mickey et al., 1977). EF43-fgf4 cells have been described
(Deroanne et al., 1997; Hajitou et al., 2001, 2002; Marchio` et al., 2004). Allmodels. Thus, this apparent limitation of in vitro models in this
soluble peptides were produced by Merrifield synthesis (AnaSpec, San Jose,experimental system suggests that evaluation of GRP78-tar-
CA and Genemed Synthesis, Inc., South San Francisco, CA). Unless other-geted treatment in mouse tumor models is more likely to be
wise specified, synthetic peptides with unrelated sequences were used as
representative of clinically relevant aspects of disease in human a negative control in binding experiments.
cancer and is entirely consistent with the in vivo work of Dong
et al. (2004). Generation of targeting vectors
DNA sequences encoding the GRP78 binding peptide motifs WIFPWIQL orFinally, GRP78 binding peptides also targeted human pros-
WDLAWMFRLPVG (Blond-Elguindi et al., 1993) were cloned into SfiI-digestedtate cancer (both organ-confined and metastatic to the bone
fUSE5 phage vectors (Smith and Scott, 1993). Briefly, 500 ng of each of themarrow), as shown by phage overlay assays (Arap et al., 2002a;
synthetic oligonucleotide templates corresponding to the displayed peptidesZurita et al., 2004). Serial sections from human prostate cancer
(Sigma-Genosys, Woodlands, TX) were converted to double-stranded DNA
at early or advanced stages yielded stronger staining when by PCR amplification with the primer set 5GTGAGCCGGCTGCCC3 and
exposed to GRP78 binding phage clones than when exposed 5TTCGGCCCCAGCGGC3 (Sigma-Genosys) and 2.5 U of Taq-DNA poly-
merase (Promega, Madison, WI) in 20 l as follows: 94C for 2 min, followedto control phage, reflecting the differential expression of GRP78
by 35 cycles at 94C for 30 s, 60C for 30 s, and 72C for 30 s, followedin the progression of prostate cancer. GRP78 binding phage
by 72C for 5 min. Double-stranded DNA sequences that contained BglIclones abrogate the binding of an anti-GRP78 antibody, pre-
restriction sites in the insert-flanking regions were purified by using a QIA-sumably due to the relatively large size of phage particles that
quick nucleotide removal kit (Qiagen, Hilden, Germany) and eluted from
can block access to the antigen. Consistently, an anti-GRP78 each QIAquick column (Qiagen) by 50 l washes with ddH2O. Oligonucleo-
antibody also blocked the staining of GRP78 binding phage. tides were digested with BglI for 2 hr at 37C, repurified, and ligated into
One might speculate on some additional aspects of the work SfiI-digested fUSE5 vector. Plasmids were electroporated into MC1061
E. coli. DNA from each of the phage clones generated was PCR amplifiedpresented here. Compared to other targets isolated by using
to verify the correct insertion and nucleotide sequence.phage display, a potential advantage of GRP78 is that its expres-
sion might allow not only ligand-directed but also transcriptional
Cell-free binding assay
tumor targeting. It remains the focus of our ongoing studies to GRP78, HSP70, HSP90 (all from Stressgen, Victoria, Canada), and BSA
characterize whether specific tumor-associated GRP78 fea- were immobilized on microtiter wells of 96-well plates overnight at 4C. Wells
tures (such as isoforms, chaperoned coreceptors, or differential were washed twice with phosphate-buffered saline (PBS), blocked with PBS
containing 3% BSA for 1 hr at room temperature (RT), and incubated withactivation states) might be present in the cell surface. Indeed,
109 transducing units (TU) of WIFPWIQL-phage, WDLAWMFRLPVG-phage,a recent study has shown that a fraction of GRP78 can exist
or insertless control phage in 50 l of PBS containing 1.5% BSA. After 2 hras a transmembrane protein capable of trafficking to tumor cell
at RT, wells were washed with PBS and bound phage clones were recoveredsurfaces (Reddy et al., 2003); thus, it is plausible that GRP78
by infection with host bacteria (log phase E. coli K91 kan; OD600 2). Aliquots
might return to the cell surface after internalization occurs, as of the bacterial culture were plated onto Luria-Bertani (LB) agar plates con-
part of a dynamic process. In yet other lines of research, GRP78 taining 40 g/ml tetracycline and 100 g/ml kanamycin (Smith and Scott,
1993; Pasqualini et al., 2001). Plates were incubated overnight at 37C, andhas also been identified by phage display on the surfaces of
phage TU were counted in triplicate plates. Increasing molar concentrationsendothelial cells in atheroma plaques (Liu et al., 2003) and of
of the corresponding synthetic peptides WIFPWIQL or WDLAWMFRLPVGmacrophages (Misra et al., 2002). These intriguing observations
were used to evaluate competitive inhibition of phage binding. All syntheticmay open new GRP78-targeting applications in nonmalignant
peptides were solubilized in a standard stock solution containing dimethyl-
conditions with a stress response such as atherosclerotic and sulfoxide (DMSO) and diluted to working concentrations for the assays.
inflammatory diseases. If so, consideration should be given to
selection of improved GRP78 ligands such as higher-affinity Cell surface binding assay
We used the biopanning and rapid analysis of selective interactive ligandssingle-chain antibodies (Adams et al., 1998; Tarli et al., 1999;
(BRASIL) method (Giordano et al., 2001) to evaluate phage binding to intactViti et al., 1999), as an alternative or in addition to peptides or
cells. In brief, cultured human prostate cancer-derived DU145 cells werepeptidomimetics.
detached with ethylenediaminetetraacetate (EDTA) and resuspended in Dul-
In summary, these data establish GRP78 expressed in the becco’s modified Eagle’s medium (DMEM) containing 1% BSA at 4  106
cell surface as a tumor target in human prostate cancer, in line cells per ml. The cell suspension (50 l) was incubated with 109 TU of
with the renewed interest in stress response proteins in prostate WIFPWIQL-phage, WDLAWMFRLPVG-phage, or insertless control phage at
4C in constant slow rotation. After 2 hr, the phage/cell mixture (aqueouscancer (Cornford et al., 2000; Lebret et al., 2003a) and other
phase) was gently transferred to the top of a nonmiscible organic phaseurological tumors (Lebret et al., 2003b). Other membrane-asso-
(200 l solution in a 400 l Eppendorf tube) consisting of dibutyl phthalate:ciated chaperones (Shin et al., 2003) may also enable ligand-
cyclohexane (9:1 [v:v], d  1.03 g ml	1) and centrifuged at 10,000 g for 10directed targeting. Indeed, it is possible that tumor-specific
min at 4C. The tube was then snap frozen in liquid nitrogen, the bottom of
conformations might be found, enabling the development of the tube was sliced off, and the cell-phage pellet was isolated. Cell mem-
high-affinity cell surface ligands against GRP78 and other stress brane bound phage were recovered by infection with the host bacteria
(Giordano et al., 2001). A polyclonal rabbit anti-GRP78 antibody (Stressgen)response proteins. On a larger context, this study lends further
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and an unrelated isotype control antibody at the same dilution, recombinant dine (DAB; DAKO). Counterstaining was achieved by a 20 s immersion in
GRP78 (Stressgen), unrelated control proteins, and synthetic cognate or 100% hematoxylin, and the slides were dehydrated (with graded alcohols
control peptides (each at 100 g/ml) were used to evaluate competitive and xylene) and mounted. All sections and controls from each specimen were
inhibition of phage binding. included in simultaneous staining runs to minimize experimental variability.
Cell internalization assay Targeted proapoptotic peptide treatment of tumor-bearing mice
Cells were grown in tissue chamber slides (Lab-Tek II Chamber Slide System; Cohorts of tumor-bearing mice were size matched and divided into groups
Nalge Nunc International Corp., Naperville, IL), washed twice with PBS, (n  7 each), and treatments started when mean tumor volumes reached
incubated with 109 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or 200 mm3; the weights of mice were also similar (5% variation) within
insertless control phage in DMEM containing 1% BSA at 37C, and washed each treatment cohort. Two GRP78-targeting peptides (WIFPWIQL or
five times with PBS to remove unbound phage after 4 hr incubation. Bound WDLAWMFRLPVG) were each synthesized as a chimera with the proapo-
phage clones to cell membranes were chemically eluted by rinsing cells with ptotic motif D(KLAKLAK)2 and used as therapy in tumor-bearing mice while
20 mM glycine at pH 2.3. Next, cells were washed three times with PBS, control tumor-bearing mice received a corresponding equimolar mixture of
fixed with PBS containing 4% paraformaldehyde (PFA) at RT for 15 min, either unconjugated WIFPWIQL plus D(KLAKLAK)2 or unconjugated WDL
washed with PBS, permeabilized with 0.2% Triton X-100, washed with PBS, AWMFRLPVG plus D(KLAKLAK)2. Mice were deeply anesthetized, and tumor
and blocked with PBS containing 1% BSA. Cells were then incubated with volumes were measured as described (Arap et al., 1998; Koivunen et al.,
a 1:200 dilution of the primary anti-M13 bacteriophage antibody (Amersham, 1999; Marchio` et al., 2004; Pasqualini et al., 2001). Therapeutic and control
Piscataway, NJ) in PBS containing 1% BSA at RT for 2 hr, washed with peptides were systemically administered (tail vein) at 300 g/dose/mouse
PBS, and incubated with a 1:200 dilution of a Cy3-conjugated anti-rabbit in 200 l of vehicle (DMEM) weekly for a period of 4 weeks.
secondary antibody in PBS containing 1% BSA for 1 hr at RT. Finally, cells
were washed with PBS, fixed with PBS containing 4% PFA, mounted, and Phage overlay and competition assay on human tissue samples
visualized in an optical fluorescence microscope. Immunohistochemistry on sections of fixed human paraffin-embedded bone
metastases from prostate cancer patients was performed with LSAB
 per-
Cell viability assay oxidase kit (DAKO). Human samples of metastatic prostate cancer patients
A total of 2  104 cells per well were seeded in 96-well plates for 24 hr in (n  6) were obtained from the University of Sa˜o Paulo Medical School,
DMEM containing 10% fetal bovine serum (FBS), incubated with increasing Brazil. Sections (5 m) were deparaffinized, rehydrated, and blocked for
concentrations of the peptides WDLAWMFRLPVG-GG-D(KLAKLAK)2 or WDL endogenous peroxidases and for nonspecific protein binding. An anti-GRP78
AWMFRLPVG and D(KLAKLAK)2 in 60 l DMEM containing 1% FBS for 2 hr goat polyclonal antibody (C-20, sc-1051; Santa Cruz Biotechnology, Santa
at 37C and with or without 20 mM sodium azide (NaN3). After 2 hr, cell Cruz, CA) and an unrelated control goat polyclonal isotype antibody (goat
viability was measured with a cell proliferation detection reagent (WST-1;
IgG-reagent grade; Sigma, St. Louis, MO) at the same immunoglobulin con-
Roche, Mannheim, Germany). All samples were performed in triplicates.
centration were used to evaluate competitive inhibition of phage binding.
Tissue sections were incubated with media alone, anti-GRP78 antibody, or
Establishment of tumor-bearing mice
control antibody at the same immunoglobulin concentration for 1 hr at RT.
Immunodeficient male athymic nu/nu (nude) mice were commercially ob-
Next, 2  109 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage, or nega-
tained (Harlan-Sprague-Dawley, Indianapolis, IN). Prostate cancer xeno-
tive control phage were incubated for 2 hr at RT. An anti-bacteriophage
grafts were established by subcutaneous administration of human DU145
antibody (Sigma) was added to the slides (150 l of a 1:500 dilution) and
cells (106 cells in 200 l DMEM) into the subcutaneous tissue of the nude
incubated for 1 hr at RT. After three washes with TBST, the peroxidase-
mice. Immunocompetent female Balb/c mice bearing mouse EF43-fgf4-
conjugated anti-rabbit secondary antibody was added. Slides were washed
derived breast tumors were established as described (Deroanne et al., 1997;
three times with TBST, developed with DAB, counterstained by a 20 s
Hajitou et al., 2001, 2002; Marchio` et al., 2004). The Internal Animal Care
immersion in 100% hematoxylin, dehydrated, and mounted. To test whether
and Use Committee of the University of Texas M.D. Anderson Cancer Center
the phage would block anti-GRP78 antibody staining, we proceeded as
(UTMDACC) reviewed and approved all animal experimentation.
follows. First, after deparaffinization, rehydration, protein, and peroxidase
blockages, 2  109 TU of WIFPWIQL-phage, WDLAWMFRLPVG-phage,
Tumor targeting in vivo
negative control phage, or media alone were added to the slides and incu-
In vivo targeting experiments with phage were performed as described (Arap
bated for 2 hr. Next, anti-GRP78 antibody or control antibody at an equivalent
et al., 1998; Koivunen et al., 1999; Kolonin et al., 2004; Marchio` et al., 2004;
immunoglobulin concentration was added to the slides and incubated forPasqualini et al., 2001). Briefly, either male nude mice bearing size-matched
1 hr at RT. Slides were washed three times with TBST, and a peroxidase-human DU145 xenografts or immunocompetent female Balb/c female mouse
conjugated secondary antibody was added. After three washes, develop-bearing EF43-fgf4-derived breast tumors were deeply anesthetized and
ment was achieved with the DAB substrate. Slides were counterstained byinjected intravenously (tail vein) with 1010 TU of WIFPWIQL-phage, WDL
hematoxylin, dehydrated, and mounted. The Institutional Review Board (IRB)AWMFRLPVG-phage, RGD-4C phage (positive control), or fd-tet phage (neg-
of the University of Sa˜o Paulo Medical School reviewed and approved allative control) in vehicle (DMEM). Cohorts of three mice with size-matched
experimentation in patient-derived samples.tumors received each set of phage clones. After 24 hr, tumor-bearing mice
were perfused through the heart with 20 ml of 4% PFA. Tumor and control
Statistical analysisorgans were dissected from each mouse and fixed in PBS containing 4%
Experimental results are expressed as mean  standard errors of the meanPFA for 24 hr. Finally, tissues were paraffin embedded and sectioned into
(SEM) of triplicate plates. Statistical significance was determined by Stu-5 m specimens for phage staining as described (Pasqualini et al., 2001).
dent’s t tests.
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